Glenmark Pharma launches MINYM GEL for acne treatment

11 Jul 2022 , 11:52 AM

Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven global pharmaceutical company, has launched India’s first topical Minocycline 4% Gel for the treatment of moderate to severe acne, under the brand name MINYM.

This is a potent antibacterial gel which exerts a strong anti-inflammatory action It also offers the lowest MIC90 (minimum Inhibitory Concentration at which it stops/prevents visible growth of 90% of isolates of bacteria) compared to the available topical antibacterial formulations.

Topical antibacterial formulations are some of the commonly used class of drugs for the treatment of acne. With no new topical formulations being launched over the last 30 years, there has been a gradual increase in resistance to the currently available topical antibacterial formulationsi ii. MINYM® Gel (Topical Minocycline 4% Gel) has been developed to address these growing concerns in treatment of acne and is safe to use in patients above 9 years of age.

Speaking at the launch, Alok Malik, Group Vice President & Head, India Formulations — Glenmark said, “Glenmark is a leader in the dermatology segment in India and has been at the forefront in providing access to the latest treatment options to the patients.

We are proud to introduce the first topical Minocycline-based – MINYM Gel, in India; proven for its potent anti-bacterial effect, anti-inflammatory action and lowest resistance, as a treatment option to patients aged 9 years and above suffering from acne.”

At around 11:54 AM, Glenmark Pharmaceuticals was trading at Rs387.30 per share down by Rs0.2 or 0.05% from its previous closing of Rs387.50 per share on the BSE.